Axxess Pharma, Inc. to Sign Exclusive License Agreement to Market and Distribute FDA Approved Prescription Cough and Cold Capsul
12 July 2010 - 10:00PM
Marketwired
Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company
specializing in the marketing and distribution of both prescription
and non-prescription medical products, is pleased to announce they
will be signing an exclusive license agreement to manufacture and
distribute a unique FDA approved high potency cough and cold
capsule. The exclusive license agreement will be signed within 2
weeks.
This capsule is currently being sold by physicians, pharmacists
and specialists in the United States. Pending final approval from
Health Canada, the high potency capsule will be sold under the
Axxess Pharma name in Canada and the Middle East. The prescription
cough and cold market currently generates over $2 billion in annual
sales worldwide.
"Our latest prescription cough and cold capsule is anticipated
to generate strong global sales for our company. Customers and
patients will no longer need to carry bottles of cough and cold
medicine. The unique capsule is easy to carry; currently FDA
approved and is soon to be approved by Health Canada. We are now in
discussion to expand the FDA approved prescription capsule into
Africa," stated Gerald Sequeira, President/CEO.
For more information, please contact Investor Relations at (973)
351-3868 or visit the company website directly:
http://www.axxesspharma.com.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that
focuses on the marketing of dermatological, therapeutic
nutritionals, pain management and diagnostic products in Canada and
abroad since 1997. Axxess owns 22 established pharmaceutical
prescription products that have proven sales in Canada and
internationally. The company has an experienced management team and
field sales force to market products nationally to hospitals and
retail pharmacies as well as specialized practice areas including
Dermatology and Nephrology, Neurology and Urology.
Safe Harbor
Statements about the Company's future expectations and all other
statements in this press release other than historical facts, are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby.
The above information contains information relating to the
Company that is based on the beliefs of the Company and/or its
management, as well as assumptions made by any information
currently available to the Company or its management. When used in
this document, the words "anticipate," "estimate," "expect,"
"intend," "plans," "projects," and similar expressions, as they
relate to the Company or its management, are intended to identify
forward-looking statements. Such statements reflect the current
view of the Company regarding future events and are subject to
certain risks, uncertainties and assumptions, including the risks
and uncertainties noted. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
to be incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated, expected,
intended or projected. In each instance, forward-looking
information should be considered in light of the accompanying
meaningful cautionary statements herein. Factors that could cause
results to differ include, but are not limited to, successful
performance of internal plans, the impact of competitive services
and pricing and general economic risks and uncertainties.
Contact: Taylor Capitol, Inc. Investor Relations Stephen Taylor
973-351-3868 Info@PennyMover.com
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jul 2023 to Jul 2024